文献速递骨肿瘤小儿骨科

荷兰儿童骨肉瘤全国集中化切除术后初步手术发现与并发症:一项基准研究

Preliminary Surgical Findings and Complications After National Centralization of Pediatric Bone Sarcoma Resections in the Netherlands: A Benchmarking Study.
PubMed 文献 · Clin Orthop Relat Res · 2025-12-10

该研究回顾性分析了2018至2024年荷兰全国儿童骨肉瘤集中化治疗后99例手术患者的围手术期与术后早期结局。结果显示3%发生严重术中并发症,R0切缘达94%,30天内22%出现并发症、11%因并发症再次手术,7%因并发症导致化疗延迟超过28天。结论认为并发症虽较多但很少延迟化疗,并提供了可供未来评估手术表现的基准指标。

要点

  • 全国集中化后99例儿童骨肉瘤手术中,R0切缘实现率为94%。
  • 30天内22%发生并发症,11%因并发症再次手术,最常见为感染和/或伤口裂开(11%)。
  • 7%因并发症术后化疗启动超过28天,但中位化疗时间为18天。

核心结论

  • 尽管并发症相当多,但很少延迟术后化疗。
  • 减少术后并发症可能有助于改善治疗连续性和结局。
  • 该全国集中化后的初步基准为未来研究评估手术表现提供了有临床意义的围手术期和术后结局指标。
  • 晚期术后并发症和肿瘤学结局将在随访时间更长后报告。

研究设计与样本

  • 回顾性分析2018年至2024年荷兰全国儿童骨肉瘤集中化治疗后0至18岁接受原发恶性骨肉瘤手术切除的患儿。
  • 排除42例集中系统治疗但在转诊成人肉瘤中心手术者及16例轴向定位者,最终纳入99例在国家儿童肿瘤中心手术者。
  • 肿瘤和治疗特征进行回顾性分析,术后并发症采用Clavien-Dindo和Henderson分类报告短期(<30天)至中期(<90天)结局。

主要发现

  • 3%(3/99)患者发生严重术中并发症,中位(范围)失血量为100 mL(50至4000)。
  • 94%(93例)患者实现R0切缘。
  • 22%(22例)患者在术后30天内发生任何并发症(感染、伤口裂开、压疮、骨折、神经血管),11%(11例)因并发症接受再次手术。
  • 最常见并发症为感染和/或伤口裂开(11%[11例]),发生1例骨折。
  • 术后化疗中位(IQR)时间为18天(16至22),7%(7例)因并发症在术后>28天开始化疗。

关键数值与推荐

  • 90天时,假体关节感染(Henderson 4a型)采用清创、抗生素和植入物保留(DAIR)治疗者占4%(4例),采用二期翻修者占2%(2例)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric bone sarcomas are rare malignancies that are usually treated with specialized multimodal care to allow specialized oncologists to gain experience and provide expertise in treatment. In the Netherlands, oncologic care for all pediatric cancers, including pediatric bone sarcoma, has been centralized in one tertiary referral center for pediatric oncology since 2018. Surgical decision-making is not solely driven by whether limb salvage is oncologically feasible, but rather by a comprehensive shared decision-making process in which all surgical options are carefully weighed against one another. This includes not only oncologic safety, but also expected functional outcomes such as sports participation, the risk of complications, and the burden of additional surgeries that may be performed over time. By openly discussing these trade-offs with patients and families, we aim to reach a decision that best aligns with the family's values and expectations, and thereby with the child's long-term well-being and priorities. The objective of this study was to provide benchmark values for future comparisons of short-term perioperative and postoperative outcomes. QUESTIONS/PURPOSES: We evaluated results following the national centralization of pediatric bone sarcoma care in the Netherlands to determine: (1) What were the intraoperative complications and blood loss? (2) What was the proportion of patients who achieved R0 margins? (3) What were the 30- and 90-day complications after surgical treatment, and what proportion had a delay in resuming chemotherapy? METHODS: Between 2018 and 2024, a total of 157 children age 0 to 18 years underwent surgical resection for primary malignant bone sarcoma. We excluded 42 patients who had centralized systemic treatment but underwent surgery at referring adult sarcoma centers and 16 patients who had an axial localization. We included 99 patients who underwent surgery at the national pediatric oncology center for osteosarcoma (n = 69), Ewing sarcoma (n = 25), or other (n = 5); the extremities were involved in most patients (91% [90]). Of these, none were lost to follow-up; 1% (1) died within the first year from other causes. Seventy percent (69 of 99) had ≥ 1 year of follow-up. Ninety-day postoperative outcomes were evaluated to capture clinically relevant short-term treatment morbidity and care continuity. Tumor and treatment characteristics were retrospectively analyzed. The median (IQR) age was 13 years (9 to 15); 36% (36) were female. The median (IQR) follow-up time was 18 months (8 to 43). Among the 99 included patients, surgical procedures included limb-sparing surgery (68% [67]), amputation (15% [15]), rotationplasty (17% [17]), and other (1% [1]). Medical charts were reviewed for blood loss and surgical margins. Postoperative complications (using the Clavien-Dindo and the Henderson classifications) are reported from short-term (< 30 days) to midterm (< 90 days). RESULTS: Three percent (3 of 99) of patients had serious intraoperative complications, and the median (range) blood loss was 100 mL (50 to 4000). R0 margins were realized in 94% (93) of patients. Twenty-two percent (22) of patients experienced any complication (infection, wound dehiscence, pressure ulcer, fracture, neurovascular) within 30 days postoperatively, with 11% (11) undergoing another operation for a complication. The most common complications were infections and/or wound dehiscence (11% [11]); one fracture occurred. The median (IQR) time to postoperative chemotherapy was 18 days (16 to 22). In 7% (7) of patients, chemotherapy was started > 28 days postoperatively because of complications. At 90 days, prosthetic joint infections (Henderson Type 4a) were treated with debridement, antibiotics, and implant retention (DAIR) (4% [4]) or a two-stage revision (2% [2]). CONCLUSION: Although complications were considerable, this seldom delayed postoperative chemotherapy. Minimizing postoperative complications may support improved treatment continuity and outcomes. This initial benchmark following national centralization of care provides clinically meaningful perioperative and postoperative outcome indicators for evaluating surgical performance in future studies; late postoperative complications and oncologic outcomes will be reported once longer follow-up becomes available. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. van Schalkwijk LHM, van der Zee JM, van Ewijk R, et al. Preliminary Surgical Findings and Complications After National Centralization of Pediatric Bone Sarcoma Resections in the Netherlands: A Benchmarking Study. Clin Orthop Relat Res. 2025. PMID: 41411180. doi:10.1097/CORR.0000000000003782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。